(RTTNews) -  Thursday, Novartis International AG (NVS: News ) said it has received approval from the German regulatory authorities for its adjuvanted cell culture-based Influenza A(H1N1) 2009 monovalent vaccine, Celtura. Novartis said it continues to pursue registration in other major countries, including Japan and Switzerland.

Celtura is manufactured in Marburg, Germany and is an MF59 adjuvanted inactivated influenza virus vaccine indicated for active immunization of persons six months of age and older against influenza disease caused by the novel pandemic A(H1N1) influenza virus. The vaccine contains 3.75 micrograms (ug) of antigen and 0.125 ml of MF59. It will be offered in multi-dose vials and in single-dose pre-filled syringes.

Click here to receive FREE breaking news email alerts for Novartis AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: contact editorial@rttnews.com